Skip to main content

Advertisement

Log in

Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The aim of this study was to investigate the effect of anti-tumor necrosis factor alpha (anti-TNF) treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis (RA). Nineteen women with RA starting anti-TNF treatment were included in the study. Disease activity, body composition, lumbar spine bone mineral density (BMD) and serum adiponectin concentrations were measured at baseline and after 1 year of follow-up. No important changes on body composition and lumbar spine BMD were observed, while the serum levels of adiponectin levels increased after 1 year of anti-TNF treatment (p = 0.02). Anti-TNF treatment in women with RA does not have any significant effect on body composition; however, it is associated with increase in adiponectin levels which may ameliorate the systemic inflammatory response state associated with RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Westhovens R, Nijs J, Taelman V et al (1997) Body composition in rheumatoid srthritis. Br J Rheumatol 36:448–448 Apr

    Article  Google Scholar 

  2. Munro R, Capell H (1997) Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Ann Rheum Dis 56:326–329

    PubMed  CAS  Google Scholar 

  3. Roubenoff R, Roubenoff RA, Cannon JG et al (1994) Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 93:2379–2386

    Article  PubMed  CAS  Google Scholar 

  4. Scherer PE, Williams S, Fogliano M et al (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749

    Article  PubMed  CAS  Google Scholar 

  5. Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295

    Article  PubMed  CAS  Google Scholar 

  6. Kontogianni MD, Dafni UG, Routsias JG et al (2004) Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 19:546–551

    Article  PubMed  CAS  Google Scholar 

  7. Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83

    Article  PubMed  CAS  Google Scholar 

  8. Hector J, Schwarzloh B, Goehring J et al (2007) TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 39:250–255

    Article  PubMed  CAS  Google Scholar 

  9. Shioji K, Moriwaki S, Takeuchi Y et al (2007) Relationship of serum adiponectin to level of adverse cardiovascular events in patients who undergo percutaneous coronary intervention. Circ J 71:675–680

    Article  PubMed  CAS  Google Scholar 

  10. Stefan N, Ehling A, Neumann E et al (2003) Adipocytokines in synovial fluid. JAMA 290:1709–1710

    Article  Google Scholar 

  11. Ehling A, Schäffler A, Herfarth H et al (2006) The potential of adiponectin in driving arthritis. J Immunol 176:4468–4478

    PubMed  CAS  Google Scholar 

  12. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850

    Article  PubMed  Google Scholar 

  13. Vis M, Havaardsholm EA, Haugeberg G et al (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and rankl serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499

    Article  PubMed  CAS  Google Scholar 

  14. Marcora SM, Chester KR, Mittal G et al (2006) Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 84:1463–1472

    PubMed  CAS  Google Scholar 

  15. Harle P, Sarzi-Puttini P, Cutolo M et al (2006) No change of serum levels of leptin and adiponectin during anti-tumor necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 65:970–971

    Article  PubMed  CAS  Google Scholar 

  16. Komai N, Morita Y, Sakuta T et al (2007) Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 17:385–390

    Article  PubMed  CAS  Google Scholar 

  17. Otero M, Lago R, Gomez R et al (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65:1198–1201

    Article  PubMed  CAS  Google Scholar 

  18. Senolt L, Pavelka K, Housa D et al (2007) Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 38:151–156

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest statement

The authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fotini N. Skopouli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Serelis, J., Kontogianni, M.D., Katsiougiannis, S. et al. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol 27, 795–797 (2008). https://doi.org/10.1007/s10067-008-0855-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-008-0855-7

Keywords

Navigation